Edgewise Therapeutics

Edgewise Posts $1.17B Q3 Profit on Servier Deal, Holds $1.74B Cash

Image
Edgewise Posts $1.17B Q3 Profit on Servier Deal, Holds $1.74B Cash

BOULDER, Colo. – November 04, 2026 -- Edgewise Therapeutics (Nasdaq: EWTX) reported third-quarter 2026 net income of $1,166.2 million, or $9.65 per diluted share, driven by a $1.348 billion gain on the sale of its sevasemten program and muscular dystrophy business to Servier. In the same period of 2025, the company posted a net loss of $40.7 million, or $0.39 per share.

Servier sale delivers $1.396 billion in upfront cash

The transaction closed in July 2026. Edgewise received $1.396 billion in upfront cash at closing. The reported gain includes consideration recognized at closing, among it amounts tied to the general indemnification arrangement. It is stated net of the carrying value of transferred assets, transaction costs and consideration allocated to transition services. Income tax expense associated with the transaction partly offset the gain in net income.

Edgewise Grants Inducement Equity to 2 New Hires at $38.90 Strike

Image
Edgewise Grants Inducement Equity to 2 New Hires at $38.90 Strike

BOULDER – November 02, 2026 -- Edgewise Therapeutics (Nasdaq: EWTX) granted inducement stock options on 17,250 shares and restricted stock units covering 8,626 shares to two new non-executive employees on October 30, 2026.

Options carry a $38.90 exercise price set at the grant-date close

Each option has an exercise price of $38.90 per share, equal to Edgewise's closing share price on the grant date. The awards were made under the company's 2024 Inducement Equity Incentive Plan.

Options vest over four years, with a one-year cliff

Twenty-five percent of the shares under each option vest on the first anniversary of the employee's start date. The remainder vest in 1/48th monthly installments, subject to continued service.

Edgewise Reveals EDG-7500 Data Targeting Novel Cardiac Muscle Protein

Image
Edgewise Reveals EDG-7500 Data Targeting Novel Cardiac Muscle Protein

Boulder, Colorado – September 22, 2026 -- Edgewise Therapeutics (Nasdaq: EWTX) disclosed preclinical data showing its lead cardiac drug candidate EDG-7500 improves heart relaxation while preserving systolic function, a mechanism the company says addresses a core driver of hypertrophic cardiomyopathy (HCM) that current therapies do not fully target.

Edgewise screened over 7,000 candidates to isolate a first-in-class RLC modulator

The company's Chief Scientific Officer, Alan Russell, said Edgewise screened more than 7,000 pharmacologically diverse compounds targeting the Regulatory Light Chain (RLC) before selecting molecules exhibiting positive lusitropic properties without compromising systolic performance. "EDG-7500's diastolic-biased profile has the potential to address a central pathologic driver of both symptomatic obstructive and nonobstructive HCM," Russell said.